Table 1 The clinico pathologic characteristics of previously reported cases of pyloric gland adenoma [2–15] and the case reported here
Author (year) | Number of cases | Age/Sex | Site | Associated lesion | Malignancy developing in PGA | Size (cm) | Immunoreactivity | Genetics |
|---|---|---|---|---|---|---|---|---|
Kushima (1996) | 1 | 61/F | Gallbladder | Gastric metaplasia | – | 1.5 | MUC6 (= M2) | n.k. |
Bakotic (1999) | 1 | 69/F | Pancreas (main duct) | Heterotopic gastric corpus mucosa | – | 0.9 | PAS, negative: Alcian blue, chromogranin, serotonin, somatostatin, gastrin | KRAS exon 1 (p.G12R; c.34G>C) |
Kushima (1999) | 1 | 67/F | Duodenum | Heterotopic gastric corpus mucosa | – | 2.5 | MUC5AC (= M1), MUC6 (= M2) | n.k. |
Kato (2002) | 1 | 70/M | Pancreas (main duct) | IPMN | – | 0.6 | PCS, HIK1083, negative: neuroendocrine markers, hormones | KRAS exon 1, codon 12 |
Amaris (2002) | 1 | 73/M | Pancreas (branch duct) | IPMN | – | n.k. | PAS, negative: Alcian blue | n.k. |
Vieth (2003) | 90 | 73/F:M = 3:1 | Stomach (n =77 ), duodenal bulb (n = 7), duodenum (n = 1), common bile duct (n = 3), gallbladder (n = 2) | Gastritis (A-, B-, and C-type) (20-34%), tubular adenoma (n = 1), carcinoid tumour (n = 1), adenocarcinoma (n = 1) | Adenocarcinoma (30%) | 1.6 | n.k. | n.k. |
Vieth (2005) | 1 | 46/M | Rectum | Heterotopic gastric corpus mucosa | – | 3 | MUC6, MUC5AC | n.k. |
Kushima (2005) | 1 | 62/M | Esophagus | Barrett's mucosa | – | 3 | MUC6, MUC5AC, negative: MUC2, CD10 | CGH: losses at 2p24p25.2, 2q14.1pter, 5q31.3q32, 6q23q24, 8q23q24.2,11q22.3q24, 18q21.1q22 |
Chen (2009) | 41 tumours, 36 patients | 73/F:M = 25:11 | Stomach (19), duodenum (19), gastroesophageal junction (2), pancreas (1) | Gastritis (A-type) (40%), intestinal metaplasia (60%) | Adenocarcinoma (12.2%) | n.k. | MUC6, MUC5AC, negative: CDX2, MUC2 | n.k. |
Wani (2008) | 29 | n.k. | Gallbladder | Intestinal metaplasia (34.4%), squamous morules (24.1%) | – | 0.82 | MUC6, MUC5AC, M-GGMC-1, morules: CDX2, beta-catenin | n.k. |
Golger (2008) | 1 | 79/F | Stomach | Helicobacter-negative gastritis | – | 2 | n.k. | n.k. |
Oh (2010) | 1 | n.k. | Stomach | – | Adenocarcinoma | 3.5 | MUC6 | n.k. |
Vieth (2010) | 60 | 70-71/F=M | Stomach | – | Adenocarcinoma (46.7%) | 0.9-1.5 | MUC6, MUC5AC (MUC2, CD10), p53 and Ki67 in malignant transition | n.k. |
Gutierrez-Grobe (2010) | 1 | 49/F | Stomach | – | – | n.k. | MUC6, MUC5AC, negative: MUC2 | n.k. |
Present case | 1 | 62/M | Cystic duct | IPN, BilIN-3 | Adenocarcinoma | 2 | MUC5AC, MUC6, VEGF, p53, p21, Ki67, (MUC1, p16), negative: MUC2, CD10, CDX2 | KRAS exon 1 (p.G12V; c.35G>T); CGH: gains at 1q, 6p11p22, 7p, 15q, 20p, and losses at 6p23pter, 6q14qter, 11q12q13, 18 |